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Abstract
We report on 4 patients (1 immunocompetent, 3 immunosuppressed) in whom visceral
leishmaniasis had become unresponsive to (or had relapsed after) treatment with appropri-
ate doses of liposomal amphotericin B. Under close follow-up, full courses of pentavalent
antimony were administered without life-threatening adverse events and resulted in rapid
and sustained clinical and parasitological cure.
Author Summary
Visceral leishmaniasis causes fever, enlargement of internal organs like the liver and the
spleen, and leads to death if no treatment is given. It is caused by a microbe called Leish-
mania and affects children and adults in warm and temperate regions of the world. Anti-
mony in different forms has been used to treat Visceral Leishmaniasis for almost one
century and is still in use in several countries despite the fact that it sometimes displays
toxic effects, especially in patients with underlying health problems. Because it is better tol-
erated and at least as effective as antimony, liposomal amphotericin B is now used as the
first treatment for Visceral Leishmaniasis in Southern Europe. We observed that a small
proportion of patients—especially those with an impaired immune system—do not cure
even after several courses of liposomal amphotericin B. In 4 such patients with “unrespon-
siveness” to liposomal amphotericin B, antimony provided a sustained cure without major
side effects. We conclude that when multiple failures or relapses occur after treatment
with liposomal amphotericin B, antimony is a reasonable, potentially life-saving treatment
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004304 January 6, 2016 1 / 7
OPEN ACCESS
Citation: Morizot G, Jouffroy R, Faye A, Chabert P,
Belhouari K, Calin R, et al. (2016) Antimony to Cure
Visceral Leishmaniasis Unresponsive to Liposomal
Amphotericin B. PLoS Negl Trop Dis 10(1):
e0004304. doi:10.1371/journal.pntd.0004304
Editor: Ricardo Toshio Fujiwara, Universidade
Federal de Minas Gerais, BRAZIL
Received: July 2, 2015
Accepted: November 24, 2015
Published: January 6, 2016
Copyright: © 2016 Morizot et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper.
Funding: The authors received no specific funding
for this work.
Competing Interests: The authors have declared
that no competing interests exist.
option. These observations also suggest that “unresponsiveness” to amphotericin B results
from unusual resistance mechanisms.
Introduction
Untreated visceral leishmaniasis (VL) is generally fatal. Although pentavalent antimony is still
used in endemic areas [1], liposomal amphotericin B (L-AmB) has become the reference treat-
ment in Europe and the US [2]. L-AmB is highly effective, generally better tolerated than pen-
tavalent antimony, and requires fewer infusions. With L-AmB, treatment failure and VL
relapse are rare in immunocompetent patients but frequent in immunocompromised patients
[3]. Prolonged evolution has been observed despite L-AmB maintenance therapy [4–6], with
poor prognosis, especially in HIV/HCV or HIV/HBV coinfected patients [7]. In such situa-
tions, high antileishmanial efficacy is required and severe adverse events are frequent. Miltefo-
sine monotherapy is moderately effective in chronic uncontrolled VL [8]. High doses of
pentamidine are toxic and paromomycin is not readily available in many countries [9]. We
report the use of pentavalent antimony in 4 VL patients responding poorly to L-AmB.
Materials and Methods
Ethics Statement
Practitioners obtained oral non-opposition from duly informed patients to perform clinical
data analysis.
From 2005 to 2013, treatment advice from a French National Reference Center for Leish-
maniasis (FNRCL) expert was sought for 25 VL patients (Fig 1A). All received L-AmB as first-
line treatment [2]; 4 became unresponsive (i.e., failure or relapse with positive Leishmania PCR
after2 complete courses (20–60 mg/kg cumulated dose/course, Fig 1B). Cure was defined as
a negative smear, culture or PCR on leukoconcentrated blood plus remission of VL signs and
symptoms with no relapse during 6 months. Relapse was defined as a positive Leishmania PCR
in any sample associated with recurrence of3 of the following markers: fever, splenomegaly,
hepatomegaly, anemia, leukopenia, thrombocytopenia, weight loss, asthenia, digestive or cuta-
neous symptoms suggestive of VL. Previous explorations had shown that patients who respond
to L-AmB have a several-Log decline in parasitemia (as assessed by quantitative PCR) in less
than 3 weeks [10]. We used a kinetoplastic DNA target [11] using the following primers and
probe: 15 pmol of direct primer (CTTTTCTGGTCCTCCGGGTAGG), 15 pmol of reverse pri-
mer (CCACCCGGCCCTATTTTACACCAA), and 50 pmol of TaqMan probe (FAM-TTTTC
GCAGAACGCCCCTACCCGC-TAMRA).
Patient 1
A 58-year-old male had a history of end-stage renal failure with 3 kidney transplantations
(1979, 1981 and 2008). He had previous chronic hepatitis B, legionellosis, chronic Q fever and
cytomegalovirus infection. The last renal transplantation was associated with acute rejection
requiring a combination of anti-thymoglobulin, plasma exchanges, rituximab, mycophenolate
mofetil 1g/d, tacrolimus 4.5mg/d and prednisone 10 mg/d. In 2004 Leishmania PCR in blood
was positive (Fig 1B). L-AmB treatment initially induced clinical cure. Relapse occurred in
August 2009 when plasma exchanges and corticosteroids boluses were administered for the
graft rejection. Fever, anemia (Hb = 9.1g/dL) and leukopenia (leukocytes = 1600/mm3) were
observed, along with 431 Leishmania per ml of blood (assessed by quantitative PCR). L-AmB
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Fig 1. “black rectangle” VL episode; “hatched rectangle” oligosymptomatic VL; BM: bonemarrow; PB: peripheral blood; LN: lymph node; BAL:
broncho-alveolar lavage; q.3.w: every 3 weeks; mo: month; quantitative PCR (N = negative; 1+ = 0.5–10; 2+ = 11–100; 3+ = 101–1000; 4+ = 1001–
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(induction total dose, 40 mg/Kg) provided improvement and reduced parasitemia to 6.9 Leish-
mania/ml. A second recurrence with fever and a rise in parasitemia to 29.6 Leishmania/ml
occurred in January 2010 during monthly maintenance administration of 3 mg/kg of L-AmB.
High-dose L-AmB was reintroduced followed by miltefosine for 4 months. Parasitemia
decreased but remained positive (0.4 Leishmania/ml) and number of CD4 lymphocytes
increased from 87 to 147/mm3. A third recurrence was reported in July 2010 with fever, 29.8
Leishmania/ml and positive Leishmania culture from venous blood. L-AmB was reintroduced,
followed by maintenance infusions for 4 months, 3 mg/Kg every 3 weeks plus downgrading of
immunosuppressive therapies. As symptoms persisted, infusions were performed once-weekly
and then twice-weekly. Parasitemia decreased from 88 to 0.6 Leishmania/ml but a fourth recur-
rence occurred in April-June 2011 with fever, leukopenia (leukocytes = 1200/mm3, CD4 lym-
phocytes = 186/mm3), anemia (Hb = 9.1g/dL) and parasitemia at 40 Leishmania/ml. Patient
refused to increase the L-AmB dose, it continued at 3 mg/Kg twice-weekly. Transplant
nephrectomy was performed in November 2011 and chronic dialysis reinstituted. In February
2012, fever, splenomegaly, anemia (Hb = 8.6g/dL) and thrombocytopenia (platelet
count = 50,000/mm3) were observed with 12,870 Leishmania/ml and 60,440 Leishmania/ml of
bronchoalveolar lavage fluid. Thereafter, meglumine antimoniate adapted to renal clearance
was administered daily for 28 days, then 1–3 times/week for maintenance. Liver function
remained normal. ECG showed a T-wave inversion but troponin remained normal. Fever and
sweats resolved, spleen size decreased from 21 to 17 cm, and blood counts normalized in 4
weeks, number of CD4 lymphocytes = 833/mm3 in June 2012,. Leishmania blood PCR and cul-
tures became negative within a month and remained negative over eight monthly evaluations
until death in January 2013 due to hypovolemic shock following a dental extraction.
Patient 2
A 15-month-old female infant from Georgia arrived in France in September 2010. She had fever,
sweats, hepatosplenomegaly, pancytopenia and 213,000 Leishmania/ml. Leishmania amastigotes
were observed in the bone marrow. There was no underlying immunosuppression. Treatment
with 20 mg/kg of L-AmB resulted in complete resolution of symptoms and parasite clearance from
the blood (PCR). Four months later, clinical symptoms recurred with 50 Leishmania/ml. The
patient was treated with L-AmB then miltefosine for 28 days, resulting in complete clinical and
parasitological response (Fig 1B). Five months later a second overt relapse occurred with typical
symptoms and 20 Leishmania/ml. The patient was treated thereafter with meglumine antimoniate
with a one-week break for QT interval prolongation. Upon EKG normalization, the course was
reinstated with no further QTmodifications. All VL clinical signs and laboratory abnormalities
resolved. The patient remained relapse-free and PCR-negative 42 months of follow-up.
Patient 3
A 37-year-old male from Georgia came to France in October 2012. He had HIV infection since
2006 inconstantly treated with HAART. Other medical conditions were adrenal insufficiency,
cirrhosis due to chronic HCV, and treatment-controlled tuberculosis. VL was diagnosed in
100000; 5+ >100000 parasites/ml). (A)Treatment advice for VL: All patients received L-AmB as first-line treatment[2]; 4 became unresponsive to L-AmB
as defined by failure or relapse with positive PCR for Leishmania after at least 2 complete courses (20–60 mg/kg cumulated dose/course). (B) Follow-up of
4 patients non-responders to L-AmB: Cure was defined as a negative smear, culture or PCR on leukoconcentrated blood plus remission of clinical signs and
symptoms of VL with no relapse during 6 months. Relapse was defined as positive Leishmania PCR (any sample) associated with recurrence of3 of the
following markers: fever, splenomegaly, hepatomegaly, anemia, leukopenia, thrombocytopenia, weight loss, asthenia, digestive or cutaneous symptoms
suggestive of VL. Patient information and consent were as per FNRCL procedures (http://www.parasitologie.univ-montp1.fr/conseil.htm). Doses of
meglumine antimoniate (Glucantime) are expressed in mg of pentavalent antimony/kg.
doi:10.1371/journal.pntd.0004304.g001
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2010 and treated in Georgia with meglumine antimoniate and L-AmB (doses and schedules
unknown). In November 2012, he presented hepatosplenomegaly, lymphadenopathies, infil-
trated cutaneous lesions, anemia, number of CD4 lymphocytes = 133/mm3, viral load< 50
copies/mL, and parasitemia of 6 Leishmania/ml. He received a course of L-AmB followed by
maintenance therapy for 5 months (Fig 1B). In May 2013, he had weight loss, hepatosplenome-
galy, anemia, number of CD4 lymphocytes = 177/mm3, viral load< 40 copies/mL and parasi-
temia of 12 Leishmania/ml. L-AmB treatment was intensified, but renal insufficiency and acute
thrombocytopenia occurred. In June, the splenomegaly and parasitemia remained unchanged.
A course of meglumine antimoniate was administered. Despite pre-existing liver disorders, the
treatment was well tolerated except for mild neutropenia. One month later, a marked clinical
improvement was observed and parasitemia decreased to 0.2 Leishmania/ml. In July, mainte-
nance treatment with miltefosine (150 mg/day for 3 months) was started. Parasitemia was neg-
ative, the number of CD4 lymphocytes increased from 169 to 540/mm3, and viral load was
undetectable. Parasitemia remained negative through 18 months.
Patient 4
A 75-year-old male from Algeria had HIV infection since 2001 treated with nevirapine and
lamivudine/zidovudine. He had cerebral toxoplasmosis, chronic hepatitis B, gastrointestinal
CMV infection, and anal squamous cell carcinoma. In 2013, the patient started treatment with
darunavir, ritonavir, raltegravir and emtricitabine. VL had been diagnosed in 2001, and treated
with L-AmB 5 mg/Kg/d for 15 days with partial improvement. Maintenance therapy of 3 mg/
kg weekly was planned but irregularly administered. Recurrence was reported in March 2011,
the infecting specie was identified as L. infantum. The number of CD4 lymphocytes was 33/
mm3, and viral load 75000 copies/mL. The patient received 40 mg/kg of L-AmB, followed by 3
mg/kg at 15-day interval. Clinical improvement was obtained but qualitative PCR remained
positive. In 2012, L-AmB infusions were administered at 3-week intervals. In 2013, a last course
of 50 mg/kg of L-AmB was administered, Despite this complete course of L-AmB, clinical
symptoms worsened (weight loss, fatigue), clinical splenomegaly was present (greater diameter
20 cm on the CT scan), and parasitemia remained positive and stable (from 126 Leishmania/
ml before treatment to 118 Leishmania/ml after completion of the course 3 weeks later).
Meglumine antimoniate was thus administered, initially at low doses (4–10 mg/kg SbV every
other day for 7 weeks) because of advanced age. Treatment was well tolerated except for mod-
erate neutropenia. Fatigue resolved and weight increased from 50 to 61 Kg. The spleen was no
longer palpable after 2 months of treatment. Number of CD4 lymphocytes increased from 75
to 134/mm3. Parasitemia cleared and remained negative through 13 months of follow-up.
Discussion
In 4 patients with VL and secondary unresponsiveness or relapse after L-AmB treatment, sec-
ond-line pentavalent antimony provided a sustained clinical and parasitological cure. A kidney
transplant recipient developed relapsing episodes and received four 28–40 mg/kg courses of
L-AmB, followed in 2 instances by prolonged L-AmB maintenance regimens. These attempts
provided neither complete parasite clearance nor complete symptom resolution between overt
episodes. In contrast, meglumine antimoniate treatment provided a sustained cure in a few
weeks. The sustained positive outcome in this case cannot be unambiguously attributed to pen-
tavalent antimony because of the patient’s underlying unstable immunosuppression. Neverthe-
less, this experience suggested that antimony could be an option in patients responding poorly
to L-AmB. An immunocompetent infant relapsed twice after initially positive responses to
L-AmB or L-AmB plus miltefosine. Again, upon treatment with antimony, sustained complete
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response was obtained. In 2 patients co-infected with HIV and L. infantum and responding
poorly to 2–3 courses of L-AmB despite undetectable viral loads, sustained cure was similarly
obtained after a single course of antimony, followed in one case by oral miltefosine. Taken
together, these observations in different age groups and underlying conditions, advocate for the
use of antimony in VL patients responding inadequately to L-AmB. L-AmB remains the antil-
eishmanial agent with the widest therapeutic window in VL and should be used first-line wher-
ever affordable for initial episodes. However, our experience confirms that unresponsiveness or
repeated relapses occur in a small proportion of L-AmB-treated VL patients, especially when
immunosuppression is present [12]. Switching from L-AmB to pentavalent antimony may be
life-saving in these cases. Patients in this report were most likely infected with L. infantum.
Whether our observations also apply to L. donovani thus remains to be fully confirmed but previ-
ous reports suggest that relapse of VL is frequent both in Indian [13] an East African [14] foci of
L. donovaniwhen patients treated with AmBisome have underlying immunosuppression.
Despite adequate antiretroviral therapy and undetectable viremia, the 2 HIV-infected
patients failed to recover immunity during L-AmB treatment. After antimony treatment how-
ever, Leishmania blood PCR became negative and numbers of CD4 lymphocytes increased.
Thus, beyond controlling the signs and symptoms of VL, the appropriate treatment of Leish-
mania infection may also contribute to the prevention of HIV-related complications. Organ
transplant recipients can develop or reactivate visceral or muco-cutaneous leishmaniasis while
under immunosuppressive therapy [15] such as high-dose prednisone [16]. In children, pentava-
lent antimony is generally effective and reasonably safe when used as a first-line therapy [1] [17]
(which further supports its use in rare, complex cases with multiple relapses after treatment with
L-AmB). By contrast, in other contexts the safety of pentavalent antimony is suboptimal, like in
9 of 59 (16%) HIV-positive Ethiopian patients treated with sodium stibogluconate for VL who
died from antimony-induced adverse events [14]. In comparison, in our study, several laboratory
abnormalities were observed, but by adapting the daily dose or administration rhythm, we were
able to treat patients with a complete initial course (equivalent to 20 mg SbV/kg/day for 28 days)
without life-threatening adverse events.
The complex histories of our 4 patients strongly suggest that L-AmB failure in VL is due to
factors other than conventional antimicrobial resistance. Leishmania amastigotes exposed in
vivo to amphotericin B for many episodes in immunosuppressed patients appear to be no less
susceptible to the drug in vitro than primary isolates [18]. Although a positive effect of anti-
mony on cell-mediated immunity cannot be excluded, we favor an hypothesis where unrespon-
siveness in patients could be related to dormant parasites, the quiescence protecting them from
the lethal effect of L-AmB through a mechanism different from conventional resistance. For
currently unknown reasons, dormant/quiescent parasites may retain sensitivity to antimony.
Larger studies are needed to determine the respective contributions of parasite quiescence to
antileishmanial agents and underlying immunosuppression in the occurrence of suboptimal
response to L-AmB.
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